Atty Docket No. 015389-002943US

PTO FAX NO.:

703-872-9306

ATTENTION:

Examiner

TELEPHONE NO.: 703-872-9305

Group Art Unit 1646

## OFFICIAL COMMUNICATION

# FOR THE PERSONAL ATTENTION OF

### EXAMINER

#### CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following document(s)in re Application of Cech et al., Application No. 09/843,676, filed April 26, 2001 for NOVEL TELOMERASE is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

#### Document(s) Attached

- 1. Fee Transmittal
- 2. Preliminary Amendment

Number of pages being transmitted, including this page: 5

Dated: December 17, 2001

hy Johnston

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (650) 326-2422

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadoro Center, 8th Floor San Francisco, CA 94111-3834 Telephone: 650-326-2400

Fax: 650-326-2422

PA 3190851 v1

PTO/SE/17 09-00)

Approved for use through 10/31/2002, OMB 06(1, 0032)

Patent and Trademark Office: U.S. DEPARTMENT OF COMPLETCE

Under the Paperwork Reduction Act of 1995, no poisons are required to respond to a collection of information unless it displays a valid OMB control is impose.

FEE TRANSMITTAL	Complete If Known									
_	Appl	Application Number 09/843,676								
for FY 2001	Filing	Filing Date April 26, 2001			7 26, 2001					
	First	First Named Inventor Cec			h, Thomas R.					
Patent fees are subject to ennual revision.	Exam	Examiner Name Not yet easigned			yet essigned					
	Grou	Group Art Unit 1646								
TOTAL AMOUNT OF PAYMENT (\$) 0	Attorney Docket No. 015389-002943US									
METHOD OF PAYMENT				FEE (	ALCULATION (continued)					
The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:		DITIONAL Entity		Entity	-					
Deposit	Large Fee Code	Fee .	Fee	Fee	Fee Description	Fea				
Account 20-1430	105	(5) 130	Code 205	( <b>5</b> ) 65	Surcharge - late filing fee or oath	Pals				
(Antibo)	127	50	227	25	Surcharge - late provisional filing fee					
Doposit	1				or cover sheet.					
Account Townsend and Townsend and Crew LLP Name	139	130	139	130	Non-English specification	$\vdash$				
Chargo Any Additional Fee Required	147 112	2,520 920*	147 712	2,520 920*	For filing a request for reexamination Requesting publication of SIR prior to	<b>-</b>				
Under 37 CFR 1.18 and 1.17	```	T	, .2	320	Examiner action	1 1				
Applicant claims small ontity status, See 37 CFR 1.27  2.  Payment Enclosed:	113	1,840°	113	1,840*	Requesting publication of SIR after Exeminer action					
2. D Payment Enclosed:	115	110	215	55	Extension for roply within first month					
☐ Check ☐ Cred(t card ☐ Morey ☐ Other	116	400	216	200	Extension for reply within second month					
Order Order	117	920	217	460	Extension for roply within third month					
FEE CALCULATION  1. BASIC FILING FEE	118	1,440	218	720	Examples for reply within fourth					
Large Entity Small Entity	128	1,960	228	980	Extansion for roply within fifth month					
Fee Fee Fee Fee Description Code (5) Code (5) Fee Paid	<b>11</b> ₽	320	218	160	Notice of Appeal					
Code (5) Code (5) Fee Paid  101 740 201 370 Utility filing fee	120	320	220	160	Filing a brief in support of an appeal					
108 330 200 165 Design filling fee	121	280	221	140	Request for oral hearing					
107 510 207 255 Plant fling fee	138	1,510	13 <del>8</del>	1,510	Petition to institute a public use proceeding	] !				
108 740 206 370 Reissuo fling fee	140	110	240	65	Petition to revive - unavoldable					
114 160 214 80 Provisional filling fee	141	1,280	241	640	Petition to revive - unintentional					
SUBTOTAL (1) (\$)	142	1,290	242	640	Utility Issue fee (or reissue)					
202101742(1)	143	480	243	220	Design leave fee					
2, EXTRA CLAIM FEES	144	620 1 <b>30</b>	244 122	210 130	Plant Issue fee Petitions to the Commissioner	<b>—</b>				
Extra Fee from Fee Claims below Paid		•			Petitions related to provisional	lacktriangledown				
Total Claims 12 -20** = 0 X \$18 = 80	123	50	123	50	sppilcations					
Independent 3 -7** = 0 X \$84 = \$0	126	180	126	180	Submission of Information Disclosure Stmt					
Multiple X =	581	40	581	40	Recording each patent essignment per property (times number of properties)					
Large Entity Small Entity Fee Fee Foe Fee Eas Danadaylan	146	740	246	370	Filing a submission after finel rejection (37 CFR § 1.129(a))					
Code (5) Code (5) Fee Description 109 18 203 9 Claims in excess of 20	149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))					
102 84 202 42 Independent claims in excess of 3	179	740	279	370	Request for Continued Examination (RCE)					
104 280 204 140 Multiple dependent claim, if not paid	169	800	169	900	Request for expedited examination					
109 84 209 42 Original patent 110 18 210 9 Reliable claims in excess of 20 and	Other fo	e (specify			of a design application					
over original patent	nojasimm	iet je shi	thorize	L d to charge any additional fees to						
SUBTOTAL (2) (\$)0   the above noted Deposit Account.										
**Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)										
SUBMITTED BY					Complete (if applicable)					
ı		1		ı	1					

1	SUBMITTED BY Complexe (d applicable)								
ı	Name (Print/Type)	Hugh Wang	Registration No_(Attorney/Agent)	47,163	Тејерћоле	650-326-2400			
	Signature	of the state of th	Utters		Date	Documber 17, 2001			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

015389-002943

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cech et al.

Application No.: 09/843,676

Filed: April 26, 2001

For: NOVEL TELOMERASE

Art Unit:

1646

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

#### IN THE CLAIMS

Please cancel claims 1-20 without prejudice to subsequent renewal or future prosecution.

Please add new claims 21-32 as follows.

21. A polypeptide containing at least 10 consecutive amino acids of the sequence provided in SEQ. ID NO:225.

- 22. The polypeptide of claim 21, containing an amino acid sequence selected from the group consisting of SEQ. ID NO:112, SEQ. ID NO:113, SEQ. ID NO:114, SEQ. ID NO:1 5, SEQ. ID NO:116, and SEQ. ID NO:117.
- 23. The polypeptide of claim 21, which does not retain the telomerase catalytic activity of native human telomerase reverse transcriptase.